Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFα monoclonal antibody for traumatic acute spinal cord injury
NCT04988425Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 2, randomised trial in spinal cord injury (SCI), sponsored by Shanghai Changzheng Hospital. Primary endpoint: American Spinal Injury Association Impairment Scale at 12 months. Status: unknown.
02
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04988425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988425.